
Financial Data and Key Metrics Changes - Zyversa Therapeutics reported that proxies have been received for 1,446,712 of the 3,619,456 shares of common stock outstanding, representing approximately 40% of the total outstanding shares, which constitutes a quorum for the meeting [6] Business Line Data and Key Metrics Changes - No specific data on business lines or key metrics changes were provided in the meeting Market Data and Key Metrics Changes - No specific market data or key metrics changes were discussed during the meeting Company Strategy and Development Direction and Industry Competition - The company approved several proposals, including the election of two Class III directors and the ratification of the independent public accounting firm, indicating a focus on governance and compliance [10][13] - The approval of amendments to the equity incentive plan suggests a strategy to attract and retain talent through equity compensation [10] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting Other Important Information - The meeting was conducted virtually to allow shareholders to participate regardless of location [1] - The final vote results will be reported in a Form 8-K to be filed within four business days [15] Q&A Session Summary - No questions were submitted during the Q&A session, and the meeting concluded without any inquiries from shareholders [16]